Ali Shafeeq Neamah Asaad AL Janabi


Background: Programmed death-ligand 1 (PD-L1) expression has been reported in several malignancies, but the expression of PD-L1 in papillary thyroid cancer (PTC) has been characterized rarely. The aim of this study was to assess PD-L1 expression and its associations with clinicopathologic factors in PTC. Methods: Immunohistochemistry staining was conducted retrospectively to evaluate the expression of PD-L1 in a total of 52 PTC tumors. The correlations between PD-L1 expressions with clinicopathologic features were analyzed. Results: PD-L1 expression was positive in 59% (28/52) of PTC tumor tissues. In clinicopathologic analyses, this positive staining of PD-L1 was highly significantly linked to Pn Stage (p = 0.001), initial metastasis (p = 0.001), Tumour size (p = 0.003) and TNM staging (p = 0.001), significantly correlated with age (p = 0.03), and gender (p = 0.05), and non-significant correlation(p = 0.269) regarding presence or absence of other related background diseases. Conclusions: PD-L1 is important in determining the aggressiveness of PTC and could predict the prognosis of patients. Therefore, inhibition of PD-L1 is suggested as a potential strategy for the treatment of advanced PTC with high expression of PD-L1.

Download Statistics



biological marker; papillary thyroid cancer; programmed death-ligand 1; survival analysis.

Citation Format